Market Blog

Opinions on $PFE and $ELY

PFE - Pfiser Inc, a global bio-pharmaceutical company, has been on a downtrend since November 2015. Analysts believe the stock is undervalued, especially post the announcement of FDA approval of the drug - Xeljanz XR (tofacitinib citrate) PFE - Pfiser Inc Fundamentals Previously closed at 30.01 Day's high 30.08 Day's low 29.51 P/E ratio 24.25 EPS 1.24   Analysts opinion PFE has a PEG ratio of 2.42, P/S of 3.79